Research programme: RIPK1 inhibitors - Denali Therapeutics/Sanofi
Latest Information Update: 28 Nov 2022
At a glance
- Originator Harvard University
- Developer Denali Therapeutics Inc; Sanofi
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Psoriasis in USA
- 28 Nov 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA
- 29 Oct 2018 Preclinical trials in Psoriasis in USA (unspecified route) before October 2018